Dr Duffy:
Dr. Duffy is joining NW Bio from Merck, where he has served as Research Scientific Director in the Keytruda® (pembrolizumab) program during the last five years. Dr. Duffy’s roles included scientific support and outreach to health care providers and national and regional scientific leaders in over 20 different solid tumors and hematologic malignancies (blood cancers and lymphomas) relating to Merck’s clinical development and commercialization of Keytruda, as well as ongoing scientific support for Merck’s Investigator-Initiated Study Program. He served as the national contact point between the scientific affairs team working with medical professionals in the field and the internal research and development team in Merck for the Keynote-024 study in first-line non-small cell lung cancer, the Keynote-522 and -756 studies in triple negative breast cancer and ER+/HER2- breast cancer, and the Keynote-641 study in metastatic prostate cancer.
Dr. Duffy also served as Scientific Affairs Strategy and Training Lead in Merck’s Global Center for Scientific Affairs for Merck’s immuno-oncology franchise for hematologic malignancies. Dr. Duffy was the recipient of numerous achievement awards during his tenure at Merck.
In his roles at Merck, Dr. Duffy has been involved in the Keytruda development program from its early days through its wide commercialization. He has gained extensive experience with clinical trial designs and strategies, clinical results and feedback from medical professionals. He has built a nationwide network with key opinion leaders in both the clinical and the scientific arenas.
News 
Market Data 
Discover 
AI
